A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles-Reference-Cited by-同舟云学术

A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles

Published:2022 Issue:43 Volume:12 Page:28104-28112
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Zuo Huaqin¹^ORCID,Tao Junxian²,Wang Manli³,Xie Xiaoyan¹,Sun Mei¹

Affiliation:

1. Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225001, P. R. China

2. Department of Endocrinology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225001, P. R. China

3. Graduate School of Dalian Medical University, Dalian, Liaoning, 116044, P. R. China

Abstract

PM–PLGA–DOX/GEM nanoparticles can enhance anti-tumor immunity by recruiting and activating cytotoxic T lymphocytes based on immunogenic activation and immunosuppressive reversion.

Funder

Natural Science Foundation of Jiangsu Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D2RA04326B

Reference37 articles.

1. Cancer statistics for adolescents and young adults, 2020

2. Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy

3. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

4. Future Challenges in Cancer Resistance to Immunotherapy

5. Cancer Evolution Constrained by the Immune Microenvironment

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer;International Journal of Nanomedicine;2024-01

2. Targeting endothelial permeability in the EPR effect;Journal of Controlled Release;2023-09

3. Efficacy and mechanism of a biomimetic nanosystem carrying doxorubicin and an IDO inhibitor for treatment of advanced triple-negative breast cancer;2023-05-22